Future Market Insights states that the market was valued at USD 257.4 million in 2025 and is anticipated to reach USD 434.1 million by 2035, at a CAGR of 5.4%
The likelihood and intensity depend on your dose and other factors specific to you
Anxiety is treated using this drug
Study participants We identified all adult (aged 20 years) patients with NAFLD and type 2 diabetes who had newly started treatment with non-insulin glucose-lowering drugs (metformin, GLP-1RAs, SGLT2 inhibitors, sulfonylureas, meglitinides, thiazolidinediones, acarbose or dipeptidyl peptidase-4 inhibitors) between 1 January 2013 and 31 December 2021
accordingly, choosing an appropriate course of therapy is more difficult
[DOI] [PubMed] [Google Scholar] 96.Callaghan M., Le Roux C., Fabre A., McCarthy C